{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:01:07Z","timestamp":1784764867703,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MET is a key driver in NSCLC yet comprehensive, multi-subtype real-world data in China are lacking. Methods: Real-world data were collected from MET-altered NSCLC patients diagnosed at a comprehensive hospital in southeastern China (July 2021\u2013December 2023). Four subgroups were analyzed: MET IHC-Positive, MET Amplification, MET Exon 14 skipping, and MET Other Mutations. Demographics, risk factors, comorbidities, pathology, co-mutation, and treatment patterns were compared. With 2-year follow-up, survival outcomes and MET-TKI benefit were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 574 patients: MET IHC-Pos (81.4%), MET-Amp (11.0%), MET-Ex14 (4.70%), and Others (2.96%). Patients were predominantly elderly, male, with\u2009&gt;\u200940% smoking history and\u2009&gt;\u200935% hypertension. Pathological specimens were mainly obtained via bronchoscopy or percutaneous lung puncture. Adenocarcinoma dominated all subtypes (&gt;\u200970%), increasing with IHC intensity in MET IHC-Pos (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). MET-Amp showed the highest advanced stage (87.3%), bone (36.5%) and brain metastasis (17.5%). TP53 was the most common co-mutation (20.7%\u201325.0%). Targeted therapy predominated (Line 1st: 54.6%, Line 2nd: 38.9%), followed by chemotherapy plus immunotherapy. The 24-month OS was lower in MET-Amp (44.4%) and MET-Ex14 (48.1%) than in MET IHC-Pos (57.2%) and Others (58.8%). The 24-month OS (MET-TKI treated vs. untreated) was: 69.2% vs. 38.5% (MET IHC-Pos 2\u2009+\u2009\/3\u2009+), 71.4% vs. 25.0% (MET-Ex14), and 47.4% vs. 42.9% (MET-Amp).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MET alterations occur predominantly in the elderly, males, and smokers. MET-Ex14 shows driver-dependent characteristics with clear MET-TKI benefit. MET-Amp presents the most aggressive phenotype. MET IHC-Pos predominates (&gt;\u200980%) with heterogeneity; the 2\u2009+\u2009\/3\u2009+\u2009may benefit from MET-TKI. These findings inform subtype-based management of MET-altered NSCLC in southeastern China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16211-y","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T02:15:09Z","timestamp":1779761709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The landscape of MET alterations in non-small cell lung cancer in Southeastern China: a real-world study"],"prefix":"10.1186","volume":"26","author":[{"given":"Sisi","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rixu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengsi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"4","key":"16211_CR1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jtho.2022.10.015","volume":"18","author":"J Remon","year":"2023","unstructured":"Remon J, Hendriks LEL, Mountzios G, Garc\u00eda-Campelo R, Saw SPL, Uprety D, et al. MET alterations in NSCLC-Current Perspectives and Future Challenges. Journal of thoracic oncology\u202f: official publication of the International Association for the Study of Lung Cancer. 2023;18(4):419\u201335.","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"},{"issue":"1","key":"16211_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","volume":"10","author":"Q Huang","year":"2025","unstructured":"Huang Q, Li Y, Huang Y, Wu J, Bao W, Xue C, et al. Advances in molecular pathology and therapy of non-small cell lung cancer. Signal Transduct Target Ther. 2025;10(1):186.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"16211_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41571-023-00733-6","volume":"20","author":"G Harada","year":"2023","unstructured":"Harada G, Yang S, Cocco E, Drilon A. Rare molecular subtypes of lung cancer. Nat Rev Clin Oncol. 2023;20(4):229\u201349.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"16211_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.20892\/j.issn.2095-3941.2024.0503","volume":"22","author":"H Feng","year":"2025","unstructured":"Feng H, Xia Y, Wang W, Xu C, Wang Q, Song Z, et al. Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration. Cancer Biol Med. 2025;22(3):237\u201365.","journal-title":"Cancer Biol Med"},{"issue":"9","key":"16211_CR5","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","volume":"9","author":"J Mazieres","year":"2023","unstructured":"Mazieres J, Paik PK, Garassino MC, Le X, Sakai H, Veillon R, et al. Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial. JAMA ONCOL. 2023;9(9):1260\u20136.","journal-title":"JAMA ONCOL"},{"issue":"Pt 2","key":"16211_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113391","volume":"143","author":"K Ding","year":"2024","unstructured":"Ding K, Liu D, Jin X, Xu Y. Exploration of efficacy of the first-line treatment for advanced non-small cell lung cancer with primary MET-amplification: Retrospective evaluation of 36 cases. INT Immunopharmacol. 2024;143(Pt 2):113391.","journal-title":"INT Immunopharmacol"},{"issue":"14","key":"16211_CR7","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s40265-021-01584-0","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Savolitinib: First Approval. Drugs. 2021;81(14):1665\u201370.","journal-title":"Drugs"},{"key":"16211_CR8","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.2147\/OTT.S241231","volume":"13","author":"Z Xu","year":"2020","unstructured":"Xu Z, Li H, Dong Y, Cheng P, Luo F, Fu S, et al. Incidence and PD-L1 Expression of MET 14 Skipping in Chinese Population: A Non-Selective NSCLC Cohort Study Using RNA-Based Sequencing. Oncotargets Ther. 2020;13:6245\u201353.","journal-title":"Oncotargets Ther"},{"issue":"9","key":"16211_CR9","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jtho.2016.05.016","volume":"11","author":"S Liu","year":"2016","unstructured":"Liu S, Gou L, Li A, Lou N, Gao H, Su J, et al. The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC. Journal of thoracic oncology\u202f: official publication of the International Association for the Study of Lung Cancer. 2016;11(9):1503\u201310.","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"},{"key":"16211_CR10","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.2147\/OTT.S231257","volume":"13","author":"H Liang","year":"2020","unstructured":"Liang H, Wang M. MET oncogene in non-small cell lung cancer: mechanism of MET dysregulation and agents targeting the HGF\/c-Met axis. OncoTargets Ther. 2020;13:2491\u2013510.","journal-title":"OncoTargets Ther"},{"issue":"1","key":"16211_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01144-9","volume":"9","author":"M Tsao","year":"2025","unstructured":"Tsao M, Sholl L, Shiller M, Illei P, Wistuba II, Beasley MB, et al. MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer. npj Precis Oncol. 2025;9(1):369.","journal-title":"npj Precis Oncol"},{"issue":"1","key":"16211_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33351-4","volume":"13","author":"F Ma","year":"2022","unstructured":"Ma F, Laster K, Dong Z. The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations. Nat Commun. 2022;13(1):5651.","journal-title":"Nat Commun"},{"key":"16211_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.lungcan.2021.06.015","volume":"159","author":"M Bittoni","year":"2021","unstructured":"Bittoni M, Yang JC, Shih J, Peled N, Smit EF, Camidge DR, et al. Real-world insights into patients with advanced NSCLC and MET alterations. Lung Cancer. 2021;159:96\u2013106.","journal-title":"Lung Cancer"},{"issue":"7","key":"16211_CR14","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.7021","volume":"22","author":"K Miura","year":"2024","unstructured":"Miura K, Shukuya T, Greenstein R, Kaplan B, Wakelee H, Kurokawa K, et al. Ancestry-, sex-, and age-based differences of gene alterations in NSCLC: from the real-world data of cancer genomic profiling tests. J Natl Compr Canc Netw. 2024;22(7):e247021.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"16211_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103680","volume":"9","author":"ML Reale","year":"2024","unstructured":"Reale ML, Passiglia F, Cappuzzo F, Minuti G, Occhipinti M, Bulotta A, et al. MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database. ESMO Open. 2024;9(9):103680.","journal-title":"ESMO Open"},{"issue":"1","key":"16211_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01864-1","volume":"16","author":"U Batra","year":"2025","unstructured":"Batra U, Singh AK, Nathany S, Dewan A, Sharma M, Amrith BP, et al. Real world experience with MET inhibitors in MET exon 14 skipping mutated non-small cell lung cancer: largest Indian perspective. Discov Oncol. 2025;16(1):286.","journal-title":"Discov Oncol"},{"issue":"2","key":"16211_CR17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.20892\/j.issn.2095-3941.2024.0200","volume":"22","author":"J Wang","year":"2025","unstructured":"Wang J, Qiu T, Ren S. Updates to the 2024 CSCO advanced non-small cell lung cancer guidelines. Cancer Biol Med. 2025;22(2):77\u201382.","journal-title":"Cancer Biol Med"},{"issue":"1","key":"16211_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14687-8","volume":"25","author":"F Li","year":"2025","unstructured":"Li F, Li F, Lu H, Zhao D. Analysis of age-related survival differences in advanced non-small cell lung cancer patients based on real-world data. BMC Cancer. 2025;25(1):1244.","journal-title":"BMC Cancer"},{"key":"16211_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.649766","volume":"11","author":"L Liu","year":"2021","unstructured":"Liu L, Kalyani FS, Yang H, Zhou C, Xiong Y, Zhu S, et al. Prognosis and concurrent genomic alterations in patients with advanced NSCLC harboring MET amplification or MET exon 14 skipping mutation treated with MET inhibitor: a retrospective study. Front Oncol. 2021;11:649766.","journal-title":"Front Oncol"},{"issue":"6","key":"16211_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jtho.2022.02.011","volume":"17","author":"NI Vokes","year":"2022","unstructured":"Vokes NI, Chambers E, Nguyen T, Coolidge A, Lydon CA, Le X, et al. Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma. J Thorac Oncol. 2022;17(6):779\u201392.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"16211_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jtho.2022.10.015","volume":"18","author":"J Remon","year":"2023","unstructured":"Remon J, Hendriks LEL, Mountzios G, Garc\u00eda-Campelo R, Saw SPL, Uprety D, et al. MET alterations in NSCLC-current perspectives and future challenges. J Thorac Oncol. 2023;18(4):419\u201335.","journal-title":"J Thorac Oncol"},{"key":"16211_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.755031","volume":"11","author":"Y Song","year":"2021","unstructured":"Song Y, Li G, Ju K, Ran W, Zhao H, Liu X, et al. Mesenchymal-epithelial transition exon 14 skipping mutation and amplification in 5,008 patients with lung cancer. Front Oncol. 2021;11:755031.","journal-title":"Front Oncol"},{"issue":"11","key":"16211_CR23","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1038\/s41388-020-01577-5","volume":"40","author":"GE Wood","year":"2021","unstructured":"Wood GE, Hockings H, Hilton DM, Kermorgant S. The role of MET in chemotherapy resistance. Oncogene. 2021;40(11):1927\u201341.","journal-title":"Oncogene"},{"issue":"4","key":"16211_CR24","first-page":"128","volume":"47","author":"KG Akers","year":"2024","unstructured":"Akers KG, Oskar S, Zhao B, Frederickson AM, Arunachalam A. Clinical outcomes of PD-1\/PD-L1 inhibitors among patients with advanced or metastatic non-small cell lung cancer with BRAF, ERBB2\/HER2, MET, or RET alterations: a systematic literature review. Journal of immunotherapy (Hagerstown, Md\u202f: 1997). 2024;47(4):128\u201338.","journal-title":"Journal of immunotherapy (Hagerstown, Md : 1997)"},{"issue":"22","key":"16211_CR25","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1158\/1078-0432.CCR-25-1735","volume":"31","author":"F Pecci","year":"2025","unstructured":"Pecci F, Li H, Di Federico A, Wu J, Chen H, Gariazzo E, et al. First-line MET tyrosine kinase inhibitors versus immunotherapy \u00b1 chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC. Clin Cancer Res. 2025;31(22):4802\u201313.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"16211_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12890-024-03437-4","volume":"25","author":"M Li","year":"2025","unstructured":"Li M, Huang J, Xing R, Du X, Wei C, Wang H. Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world. BMC Pulm Med. 2025;25(1):35.","journal-title":"BMC Pulm Med"},{"issue":"10","key":"16211_CR27","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S1470-2045(24)00441-8","volume":"25","author":"J Wolf","year":"2024","unstructured":"Wolf J, Hochmair M, Han J, Reguart N, Souquet P, Smit EF, et al. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol. 2024;25(10):1357\u201370.","journal-title":"Lancet Oncol"},{"issue":"4","key":"16211_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(4):249\u201374.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"16211_CR29","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1200\/JCO.20.03570","volume":"39","author":"NH Hanna","year":"2021","unstructured":"Hanna NH, Robinson AG, Temin S, Baker SJ, Brahmer JR, Ellis PM, et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol. 2021;39(9):1040\u201391.","journal-title":"J Clin Oncol"},{"key":"16211_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241279715","volume":"16","author":"S Zhan","year":"2024","unstructured":"Zhan S, Li J, Cheng B, Li C, Feng Y, Fan L, et al. Landscape of C-MET overexpression in non-small cell lung cancer: a large-scale study of clinicomolecular features and prognosis based on Chinese data. Ther Adv Med Oncol. 2024;16:12724451.","journal-title":"Ther Adv Med Oncol"},{"issue":"25","key":"16211_CR31","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.24.00720","volume":"42","author":"DR Camidge","year":"2024","unstructured":"Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial. J Clin Oncol. 2024;42(25):3000\u201311.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16211-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16211-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16211-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:04:44Z","timestamp":1784761484000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16211-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16211"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16211-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies were approved by Ethics Committee in Clinical Research of the First Affiliated Hospital of Wenzhou Medical University (Approval Number: KY2024-R069). The studies were conducted in accordance with the local legislation and institutional requirements. This study is a retrospective study and informed consent was waived.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"883"}}